TrialCancer immunology, immunotherapy : CII2022

A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma.

Eiji Kiyohara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.